This presentation will provide an overview of key elements of early-stage drug development to consider when seeking translational funding. It will delve into the significance of protein target selection, pharmacological target validation, and clinical tractability, emphasizing the importance of these factors to funding groups. The presentation will extend to descriptions of unmet medical need, the Target Product Profile (TPP), and the Target Candidate Profile (TCP), as well as commercial factors. Lastly, the presentation sheds light on the translational funding landscape, offering insights into various sources of support that can accelerate the translation of scientific discoveries from the academic laboratory to the clinic.
Jon Collins is the CSO of Pinnacle Hill and Director of Therapeutic Research Translation at UNC Chapel Hill. Prior to joining UNC, he served as Director of the Discovery Partnerships with Academia at GSK where he led joint academia-GSK drug discovery collaborations across the US. He has 29 years’ experience leading drug development teams across all phases of early drug discovery. He received a PhD in Organic Chemistry from Indiana University at Bloomington.
Bryan Baines is Director of Scientific Collaborations and Liaison to Four Points Innovation, a strategic partnership focused on supporting and accelerating the translation of Duke R&D projects throughout preclinical stages of drug discovery and development. Bryan brings more than 30 years of broad knowledge and business experience in the biopharmaceutical industry and in-depth understanding of preclinical and clinical drug development, IP protection, and licensing.
Webinar presented on July 30, 2024 to an invited audience.
This video is provided for educational purposes only.
Download slides